ethyl 2-(5-amino-3-tert-butyl-1H-pyrazol-1-yl)acetate | 306818-06-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 2-(5-amino-3-tert-butyl-1H-pyrazol-1-yl)acetate
• 英文别名: ethyl 2-(5-amino-3-tert-butylpyrazol-1-yl)acetate
• CAS: 306818-06-4
• 化学式: C₁₁H₁₉N₃O₂
• mdl: MFCD18307205
• 分子量: 225.291
• InChiKey: NKLKNVALGKYXRM-UHFFFAOYSA-N

物化性质

• 沸点：
  355.3±37.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.636
• 拓扑面积：
  70.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  ethyl 2-(5-amino-3-tert-butyl-1H-pyrazol-1-yl)acetate 在 sodium hydroxide 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 20.0h， 生成 N-(N'-(carboxymethyl)-3-tert-butyl-5-pyrazolyl)-N'-(2,3-dichlorophenyl)urea
  参考文献：
  名称：

  1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors

  摘要：

  Inhibitors of the MAP kinase p38 are potentially useful for the treatment of arthritis and osteoporosis. Several 2,3-dichlorophenyl ureas were identified as small-molecule inhibitors of p38 by a combinatorial chemistry effort. Optimization for cellular potency led to the discovery of a new class of potent and selective p38 kinase inhibitors, exemplified by the 1-phenyl-5-pyrazolyl urea 7 (IC50 = 13 nM). (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00272-9
• 作为产物：
  描述：

  新戊酰基乙腈 、 肼基乙酸乙酯盐酸盐 在 N,N-二异丙基乙胺 作用下， 以 甲苯 为溶剂， 反应 0.25h， 生成 ethyl 2-(5-amino-3-tert-butyl-1H-pyrazol-1-yl)acetate
  参考文献：
  名称：

  Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD)

  摘要：

  Discovery of a new class of DFG-out p38α kinase inhibitors with no hinge interaction is described. A computationally assisted, virtual fragment-based drug design (vFBDD) platform was utilized to identify novel non-aromatic fragments which make productive hydrogen bond interactions with Arg 70 on the αC-helix. Molecules incorporating these fragments were found to be potent inhibitors of p38 kinase. X-ray co-crystal structures confirmed the predicted binding modes. A lead compound was identified as a potent (p38α IC(50)=22 nM) and highly selective (≥ 150-fold against 150 kinase panel) DFG-out p38 kinase inhibitor.

  DOI：

  10.1016/j.bmcl.2011.09.078

文献信息

• UREA INHIBITORS OF MAP KINASES
  申请人：NGUYEN Duyan

  公开号：US20100041642A1

  公开（公告）日：2010-02-18

  Urea containing compounds that inhibit MAP kinases, pharmaceutical compositions including such compounds and methods for using these compounds to treat inflammatory diseases and cancer are described herein.

  本文描述了含有抑制MAP激酶的尿素类化合物、包括这些化合物的药物组合物以及使用这些化合物治疗炎症性疾病和癌症的方法。
• RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Abraham Sunny

  公开号：US20110118245A1

  公开（公告）日：2011-05-19

  Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O) t ; R a is O or S.

  提供了按照公式(I)的化合物、组合物和方法，用于调节RAF激酶的活性，包括BRAF激酶，并用于治疗、预防或缓解由RAF激酶介导的一种或多种疾病或障碍的症状。公式(I)：或其药学上可接受的盐、溶剂化合物、包合物或水合物，其中X为O或S(O)t；R为O或S。
• RAF kinase modulator compounds and methods of use thereof
  申请人：Ambit Biosciences Corporation

  公开号：US08969587B2

  公开（公告）日：2015-03-03

  Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.

  本发明提供了用于调节RAF激酶活性的化合物、组合物和方法，包括BRAF激酶，并用于治疗、预防或改善由RAF激酶介导的一种或多种疾病或障碍的症状。
• 1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES
  申请人：Ambit Biosciences Corporation

  公开号：EP2947072A1

  公开（公告）日：2015-11-25

  Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. The compound is 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea, having the structure or a pharmaceutically acceptable salt, solvate, clathrate or hydrate thereof.

  本发明提供了用于调节 RAF 激酶（包括 BRAF 激酶）活性以及治疗、预防或改善由 RAF 激酶介导的疾病或紊乱的一种或多种症状的化合物、组合物和方法。 该化合物为 1-(3-(6,7-二甲氧基喹唑啉-4-氧基)苯基)-3-(5-(1,1,1-三氟-2-甲基丙-2-基)异恶唑-3-基)脲，其结构为 或其药学上可接受的盐、溶液、凝胶或水合物。
• QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF
  申请人：Ambit Biosciences Corporation

  公开号：EP2268623B1

  公开（公告）日：2015-05-06